Eli Lilly (LLY) -3.8% premarket after forecasting a steeper-than-expected earnings drop in 2012...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY) -3.8% premarket after forecasting a steeper-than-expected earnings drop in 2012 due to the expiration of a patent protecting its top-selling Zyprexa antipsychotic drug. LLY projects EPS of $3.10-$3.20 in 2012, below $3.60 consensus, and expects Zyprexa revenue to plunge by more than $3B vs. $5B-plus in sales during 2010.